Monday, February 13, 2017

M Pharmaceutical appoints Thompson president, CEO

2017-02-13 06:55 ET - News Release

Dr. Christopher Andrews reports
M Pharmaceutical Inc. has appointed Gary Thompson of Fort Thomas, Ky., to the serve as its president and chief executive officer. Mr. Thompson has served as the president and CEO of the company's U.S. subsidiary, M Pharmaceutical USA Inc., since Aug. 2, 2016, a role he will continue to fill going forward. Brian Keane, who has served as interim president and CEO of M Pharmaceutical Inc., will continue to advise the company in the capacity of senior business consultant.

"This is a natural evolution of our company," said director Dr. Christopher Andrews. "Gary Thompson delivers an intimate knowledge and understanding of our pipeline products, including C-103 and ToConceive, combined with the ambition and vision to lead all aspects of the M Pharma strategy as the company focuses on developing and commercializing innovative drug treatments and biomedical technologies applied to improving outcomes in the obesity and women's health spaces."

Mr. Thompson has over 30 years of sales and management experience in Fortune 500 health care organizations and start-up pharmaceutical companies. He has served as vice-president of sales for Cigna Healthcare, managing billions of assets over his career. Most recently, he has had management and leadership roles at several start-up ventures that have obtained patents for innovative technologies including ToConceive LLC (510K Food and Drug Administration clearance) in the women's health and wellness space and with C-103, reformulated orlistat, in the obesity space. He is a graduate of Northern Kentucky University, with a BS in kinesiology. Mr. Thompson is also a chairman of the board of Nehemiah Vision Ministries based in Chambrun, Haiti, a registered 501(c)(3) non-profit organization.

"The team, resources and pipeline that we have strategically developed at M Pharmaceutical Inc. will allow us to establish a high-profile position in the obesity and women's health spaces," said Mr. Thompson. "I am excited to contribute my leadership to the company in order to bring our drug treatments and biomedical technologies to market with the aim of improving the quality of life for so many people."

About M Pharmaceutical Inc.
M Pharmaceutical is a clinical-stage company developing innovative technologies for obesity and weight management. In addition to its recent acquisition of C-103, a reformulation of orlistat from Chelatexx LLC, the company will focus on the development of its Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity, for which it has exclusive rights. The company has also recently acquired an FDA-cleared fertility product branded as ToConceive that represents its first offering in the women's health field.
We seek Safe Harbor.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.